ELI LILLY AND COMPANY |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.3 USD | +4.85% |
|
+8.81% | +59.34% |
| 09:10pm | Employer coverage for weight-loss drugs rises sharply, survey finds | RE |
| 06-12 | Eli Lilly Gets FDA Approval for Selpercatinib to Treat Thyroid Cancer | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 42.98B 3,368B | Sales 2025 * | 52.62B 4,124B | Capitalization | 781B 61,193B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 935B | Net income 2025 * | 16.55B 1,297B | EV / Sales 2024 * | 18.6 x |
| Net Debt 2024 * | 18.07B 1,416B | Net Debt 2025 * | 15B 1,175B | EV / Sales 2025 * | 15.1 x |
| P/E ratio 2024 * |
64.9
x | P/E ratio 2025 * |
46.7
x | Employees | 43,000 |
| Yield 2024 * |
0.6% | Yield 2025 * |
0.69% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
| 1 day | +4.85% | ||
| 1 week | +8.81% | ||
| Current month | +8.81% | ||
| 1 month | +12.70% | ||
| 3 months | +9.49% | ||
| 6 months | +58.30% | ||
| Current year | +59.34% |
1 week
15.50
17.50
1 month
14.1018.00
Current year
10.8618.00
1 year
8.1018.00
3 years
5.6118.00
5 years
5.6118.00
10 years
5.6118.00
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 31/12/95 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 15/10/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 24/01/21 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 31/03/09 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 31/12/04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/06/24 | 17.3 | +4.85% | 54 |
| 11/06/24 | 16.5 | +3.12% | 192 |
| 10/06/24 | 16 | +1.27% | 149 |
| 07/06/24 | 15.8 | -1.25% | 77 |
| 06/06/24 | 16 | +0.63% | 181 |
End-of-day quote Buenos Aires S.E., June 11, 2024
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
867.3
USD
Average target price
855.4
USD
Spread / Average Target
-1.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.20% | 350B | |
| +18.67% | 330B | |
| +7.48% | 293B | |
| +16.91% | 248B | |
| +0.53% | 221B | |
| +11.06% | 217B | |
| +3.64% | 162B | |
| -3.96% | 157B | |
| -2.04% | 121B |
- Stock Market
- Equities
- LLY Stock
- LLYD Stock
